IL8 Antibody
Purified Mouse Monoclonal Antibody (Mab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | P10145 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | IgG2b |
Calculated MW | 20 KDa |
Gene ID | 3576 |
---|---|
Other Names | (Ala-IL-8)77;(Ser-IL-8)72;3 10C;310C;AMCF 1;AMCF1;b ENAP;Bbeta thromboglobulin like protein;Beta thromboglobulin like protein;C-X-C motif chemokine 8;CXC chemokine ligand 8;CXCL 8;CXCL8;Emoctakin;GCP 1;GCP-1;GCP/IL-8 protein I;GCP/IL-8 protein II;GCP/IL-8 protein III;GCP/IL-8 protein IV;GCP/IL-8 protein V;GCP/IL-8 protein VI;GCP1; Granulocyte chemotactic protein 1;IL 8;IL-8;IL-8(1-77);IL-8(9-77);IL8;IL8/NAP1 form I;IL8/NAP1 form II;IL8/NAP1 form III;IL8/NAP1 form IV;IL8/NAP1 form V;IL8/NAP1 form VI;IL8_HUMAN; Inteleukin 8;Interleukin8;K 60;K60;LECT;LUCT; Lymphocyte derived neutrophil activating factor;Lymphocyte-derived neutrophil-activating factor;LYNAP;MDNCF;MDNCF-b;MDNCF-c; MONAP;Monocyte derived neutrophil activating peptide;Monocyte derived neutrophil activating protein; Monocyte derived neutrophil chemotactic factor;Monocyte-derived neutrophil chemotactic factor;Monocyte-derived neutrophil-activating peptide;NAF;NAP 1; NAP-1;NAP1;Neutrophil activating factor;Neutrophil activating peptide 1;Neutrophil activating protein 1;Neutrophil-activating factor;Neutrophil-activating protein 1; Protein 3 10C; Protein 3-10C;SCYB 8;SCYB8;Small inducible cytokine subfamily B member 8; T cell chemotactic factor;T-cell chemotactic factor;TSG 1;TSG1; |
Dilution | WB~~1:500 |
Format | Purified mouse monoclonal in PBS(pH 7.4) containing with 0.09% (W/V) sodium azide and 50% glycerol. |
Storage | Store at -20 °C.Stable for 12 months from date of receipt |
Name | CXCL8 |
---|---|
Synonyms | IL8 |
Function | Chemotactic factor that mediates inflammatory response by attracting neutrophils, basophils, and T-cells to clear pathogens and protect the host from infection (PubMed:18692776, PubMed:7636208). Also plays an important role in neutrophil activation (PubMed:2145175, PubMed:9623510). Released in response to an inflammatory stimulus, exerts its effect by binding to the G-protein-coupled receptors CXCR1 and CXCR2, primarily found in neutrophils, monocytes and endothelial cells (PubMed:1840701, PubMed:1891716). G-protein heterotrimer (alpha, beta, gamma subunits) constitutively binds to CXCR1/CXCR2 receptor and activation by IL8 leads to beta and gamma subunits release from Galpha (GNAI2 in neutrophils) and activation of several downstream signaling pathways including PI3K and MAPK pathways (PubMed:11971003, PubMed:8662698). |
Cellular Location | Secreted. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.
References
Schmid J.,et al.J. Immunol. 139:250-256(1987).
Matsushima K.,et al.J. Exp. Med. 167:1883-1893(1988).
Mukaida N.,et al.J. Immunol. 143:1366-1371(1989).
Kowalski J.,et al.Mol. Cell. Biol. 9:1946-1957(1989).
Hotta K.,et al.Immunol. Lett. 24:165-169(1990).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.